Takeda

Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million

GSK, Takeda and others notch key clinical wins in tough-to-treat diseases

From hepatitis B to melanoma, recent study results show innovative approaches are gaining ground.

Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict

Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.

Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion

The global hepatic cirrhosis market is expanding rapidly, fueled by increasing liver disease cases, advanced treatment options, and improved healthcare infrastructure. Conditions like hepatitis, alcohol abuse, and metabolic dysfunction-associated steatotic liver disease (MASLD) are elevating cirrhosis prevalence, especially in regions with factors like high alcohol consumption. Innovative treatments, including antiviral drugs and antifibrotic agents, are gaining traction, though challenges such

Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality

Trading the abstract allure of AI hype for a technical implementation roadmap, Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Boston concluded with heavyweights from Sanofi, Takeda, AbbVie, Regeneron, Biogen, Eli Lilly, Novo Nordisk, J&J, and Broad Institute establishing that the industry's digital future now rests on the 'first mile' of lab data integrity.